For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Gilead Sciences (GILD) been one of those stocks this year?

Board member Mick Hitchcock, named interim CEO replacing Thomas Butler.COO and President Ramses Erdtmann continuing at Biomea in current ...

Gilead Sciences Inc. closed 10.06% short of its 52-week high of $119.96, which the company achieved on March 10th.

As previously reported, Guggenheim initiated coverage of Assembly Biosciences (ASMB) with a Buy rating and $31 price target. There remains a ...